Purple Biotech Ltd (PPBT) News
Filter PPBT News Items
PPBT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PPBT News Highlights
- For PPBT, its 30 day story count is now at 2.
- Over the past 6 days, the trend for PPBT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about PPBT are DEC and DRUG.
Latest PPBT News From Around the Web
Below are the latest news stories about PURPLE BIOTECH LTD that investors may wish to consider to help them evaluate PPBT as an investment opportunity.
Purple Biotech Appoints Dr. Yael Margolin to its Board of DirectorsDr. Margolin brings 35 years of expertise in biotechnology, pharma, and venture capital Purple Biotech also announces the resignation of Mr. Fabien Sebille, who served as the Company’s Chief Business Officer REHOVOT, Israel, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistan |
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer TrialThis acceleration of recruitment is expected to result in earlier look at overall survival of patients REHOVOT, Israel, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced it has completed patient enrollment in a Phase 2 study of CM24, a multi-functional im |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayIt's time to start the trading week with a look at the biggest pre-market stock movers worth watching for Monday morning! |
Purple Biotech Reports Third Quarter 2023 Financial ResultsInitial Activity in Head and Neck Cancer Demonstrated in NT219 Phase 1/2 Dose Escalation Study Patients’ Enrollment in the Phase 2 Randomized CM24 Pancreatic Cancer Trial Ahead of Timelines Cash Runway Extended to 2H 2025 through Recent Financing REHOVOT, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome |
Purple Biotech Fortifies NT219 Patent ProtectionNew patent granted in China for pharmaceutical composition of NT219 expands IP protection REHOVOT, Israel, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced that the China National Intellectual Property Administration (“CNIPA”) has granted a new patent fo |
Purple Biotech Announces Closing of $5 Million Registered Direct OfferingREHOVOT, Israel, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced the closing of its previously announced registered direct offering of 4,347,827 of the Company’s American Depositary Shares (“ADSs”) (or ADS equivalents), each ADS representing 10 ordinary |
Purple Biotech Announces $5 Million Registered Direct OfferingREHOVOT, Israel, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced that it has entered into a definitive agreement for the purchase and sale of 4,347,827 of the Company’s American Depositary Shares (“ADSs”) (or ADS equivalents), each ADS representing 10 o |
Purple Biotech Reports Potential Biomarker Data Support CM24’s Mechanism of ActionREHOVOT, Israel, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today reported new biomarker data for its lead oncology drug, CM24, a first-in-class anti-CEACAM1 monoclonal antibody. Data were presented at the American Association for Cancer Research (AACR) Special Co |
Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck CancerAnti-tumor activity noted in the highest dose cohort of NT219 in combination with cetuximab; 2 out of 4 SCCHN patients at the highest dose cohort demonstrated a confirmed partial responseNT219 exposure at the highest dose level reaching human equivalent dose for efficacy based on animal models Target engagement was confirmed in patients’ tissue biopsiesPhase 2 study of NT219 in combination with cetuximab in 2L SCCHN, is being designed REHOVOT, Israel, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Purple Bio |
Purple Biotech to Present New CM24 Pancreatic Cancer Biomarker Data at AACR Special Conference on September 28, 2023REHOVOT, Israel, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced it will present a poster titled: “Phase 1 Study of CM24 in Combination with Nivolumab in Patients with Advanced Pancreatic Cancer – Survival, Potential Biomarker and Effect on Neutrophil |